Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1959 1
1960 1
1962 1
1963 3
1964 4
1965 9
1966 4
1967 7
1968 4
1969 7
1970 8
1971 8
1972 8
1973 8
1974 9
1975 12
1976 21
1977 21
1978 23
1979 14
1980 12
1981 20
1982 22
1983 33
1984 48
1985 48
1986 47
1987 80
1988 68
1989 58
1990 37
1991 55
1992 47
1993 59
1994 53
1995 70
1996 66
1997 50
1998 76
1999 77
2000 81
2001 115
2002 108
2003 93
2004 106
2005 83
2006 83
2007 119
2008 78
2009 119
2010 101
2011 115
2012 117
2013 104
2014 125
2015 131
2016 165
2017 135
2018 155
2019 192
2020 195
2021 214
2022 198
2023 112

Text availability

Article attribute

Article type

Publication date

Search Results

3,904 results

Results by year

Filters applied: . Clear all
Page 1
Genetic and chemical inhibition of IRF5 suppresses pre-existing mouse lupus-like disease.
Ban T, Kikuchi M, Sato GR, Manabe A, Tagata N, Harita K, Nishiyama A, Nishimura K, Yoshimi R, Kirino Y, Yanai H, Matsumoto Y, Suzuki S, Hihara H, Ito M, Tsukahara K, Yoshimatsu K, Yamamoto T, Taniguchi T, Nakajima H, Ito S, Tamura T. Ban T, et al. Among authors: nishimura k. Nat Commun. 2021 Jul 19;12(1):4379. doi: 10.1038/s41467-021-24609-4. Nat Commun. 2021. PMID: 34282144 Free PMC article.
Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinoma.
Uchimoto T, Fukushima T, Komura K, Fukuokaya W, Adachi T, Hashimoto T, Yoshizawa A, Nakamura K, Yano Y, Nishimura K, Nishio K, Nakamori K, Iwatani K, Yamamoto S, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Inamoto T, Miki J, Kimura T, Ohno Y, Shiroki R, Egawa S, Azuma H. Uchimoto T, et al. Among authors: nishimura k. BJU Int. 2023 Apr;131(4):477-485. doi: 10.1111/bju.15893. Epub 2022 Sep 26. BJU Int. 2023. PMID: 36098556
Increased BUB1B/BUBR1 expression contributes to aberrant DNA repair activity leading to resistance to DNA-damaging agents.
Komura K, Inamoto T, Tsujino T, Matsui Y, Konuma T, Nishimura K, Uchimoto T, Tsutsumi T, Matsunaga T, Maenosono R, Yoshikawa Y, Taniguchi K, Tanaka T, Uehara H, Hirata K, Hirano H, Nomi H, Hirose Y, Ono F, Azuma H. Komura K, et al. Among authors: nishimura k. Oncogene. 2021 Oct;40(43):6210-6222. doi: 10.1038/s41388-021-02021-y. Epub 2021 Sep 20. Oncogene. 2021. PMID: 34545188 Free PMC article.
Whole-body MRI: detecting bone metastases from prostate cancer.
Nakanishi K, Tanaka J, Nakaya Y, Maeda N, Sakamoto A, Nakayama A, Satomura H, Sakai M, Konishi K, Yamamoto Y, Nagahara A, Nishimura K, Takenaka S, Tomiyama N. Nakanishi K, et al. Among authors: nishimura k. Jpn J Radiol. 2022 Mar;40(3):229-244. doi: 10.1007/s11604-021-01205-6. Epub 2021 Oct 25. Jpn J Radiol. 2022. PMID: 34693502 Free PMC article. Review.
Prognostic value of the fluctuation in the neutrophil-lymphocyte ratio at 6 weeks of pembrolizumab treatment is specific to the clinical response in metastatic urothelial carcinoma.
Uchimoto T, Nakamura K, Komura K, Fukuokaya W, Yano Y, Nishimura K, Kinoshita S, Nishio K, Fukushima T, Nakamori K, Matsunaga T, Tsutsumi T, Tsujino T, Taniguchi K, Tanaka T, Uehara H, Takahara K, Inamoto T, Kimura T, Egawa S, Azuma H. Uchimoto T, et al. Among authors: nishimura k. Urol Oncol. 2022 Jul;40(7):344.e11-344.e17. doi: 10.1016/j.urolonc.2022.02.012. Epub 2022 Mar 26. Urol Oncol. 2022. PMID: 35346572
Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study.
Roubaud G, Özgüroğlu M, Penel N, Matsubara N, Mehra N, Kolinsky MP, Procopio G, Feyerabend S, Joung JY, Gravis G, Nishimura K, Gedye C, Padua C, Shore N, Thiery-Vuillemin A, Saad F, van Alphen R, Carducci MA, Desai C, Brickel N, Poehlein C, Del Rosario P, Fizazi K. Roubaud G, et al. Among authors: nishimura k. Eur J Cancer. 2022 Jul;170:73-84. doi: 10.1016/j.ejca.2022.04.016. Epub 2022 May 19. Eur J Cancer. 2022. PMID: 35598359 Free article. Clinical Trial.
Clinical Characteristics and Outcomes of Hospitalized Patients With Heart Failure From the Large-Scale Japanese Registry Of Acute Decompensated Heart Failure (JROADHF).
Ide T, Kaku H, Matsushima S, Tohyama T, Enzan N, Funakoshi K, Sumita Y, Nakai M, Nishimura K, Miyamoto Y, Tsuchihashi-Makaya M, Hatano M, Komuro I, Tsutsui H; JROADHF Investigators. Ide T, et al. Among authors: nishimura k. Circ J. 2021 Aug 25;85(9):1438-1450. doi: 10.1253/circj.CJ-20-0947. Epub 2021 Apr 15. Circ J. 2021. PMID: 33853998 Free article.
Olaparib in patients with mCRPC with homologous recombination repair gene alterations: PROfound Asian subset analysis.
Matsubara N, Nishimura K, Kawakami S, Joung JY, Uemura H, Goto T, Kwon TG, Sugimoto M, Kato M, Wang SS, Pang ST, Chen CH, Fujita T, Nii M, Shen L, Dujka M, Hussain M, de Bono J. Matsubara N, et al. Among authors: nishimura k. Jpn J Clin Oncol. 2022 May 5;52(5):441-448. doi: 10.1093/jjco/hyac015. Jpn J Clin Oncol. 2022. PMID: 35229141 Free PMC article. Clinical Trial.
Dysregulated minor intron splicing in cancer.
Nishimura K, Yamazaki H, Zang W, Inoue D. Nishimura K, et al. Cancer Sci. 2022 Sep;113(9):2934-2942. doi: 10.1111/cas.15476. Epub 2022 Jul 11. Cancer Sci. 2022. PMID: 35766428 Free PMC article. Review.
3,904 results